201 related articles for article (PubMed ID: 30941657)
1. The Impact of Signet Ring Cell Differentiation on Outcome in Patients with Esophageal and Gastroesophageal Junction Adenocarcinoma.
van Hootegem SJM; Smithers BM; Gotley DC; Brosda S; Thomson IG; Thomas JM; Gartside M; van Lanschot JJB; Lagarde SM; Wijnhoven BPL; Barbour AP
Ann Surg Oncol; 2019 Aug; 26(8):2375-2384. PubMed ID: 30941657
[TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant Therapy Improves Outcomes in Locally Advanced Signet-Ring-Cell Containing Esophagogastric Adenocarcinomas.
Heger U; Sisic L; Nienhüser H; Blank S; Hinz U; Haag GM; Ott K; Ulrich A; Büchler MW; Schmidt T
Ann Surg Oncol; 2018 Aug; 25(8):2418-2427. PubMed ID: 29855828
[TBL] [Abstract][Full Text] [Related]
3. Is preoperative chemotherapy followed by surgery the appropriate treatment for signet ring cell containing adenocarcinomas of the esophagogastric junction and stomach?
Heger U; Blank S; Wiecha C; Langer R; Weichert W; Lordick F; Bruckner T; Dobritz M; Burian M; Springfeld C; Grenacher L; Siewert JR; Büchler M; Ott K
Ann Surg Oncol; 2014 May; 21(5):1739-48. PubMed ID: 24419755
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant chemoradiotherapy improves survival in locally advanced adenocarcinoma of esophagogastric junction compared with neoadjuvant chemotherapy: a propensity score matching analysis.
Li J; Zhao Q; Ge X; Song Y; Tian Y; Wang S; Liu M; Qiao X
BMC Surg; 2021 Mar; 21(1):137. PubMed ID: 33731072
[TBL] [Abstract][Full Text] [Related]
5. Esophageal adenocarcinoma with any component of signet ring cells portends poor prognosis and response to neoadjuvant therapy.
Corsini EM; Foo WC; Mitchell KG; Zhou N; Maru DM; Ajani JA; Hofstetter WL; ; Correa AM; Antonoff MB; Lin SH; Mehran RJ; Rajaram R; Rice DC; Roth JA; Sepesi B; Swisher SG; Vaporciyan AA; Walsh GL
J Thorac Cardiovasc Surg; 2021 Nov; 162(5):1404-1412.e2. PubMed ID: 33010880
[TBL] [Abstract][Full Text] [Related]
6. [Neoadjuvant chemoradiotherapy combined with surgery versus direct surgery in the treatment of Siewert type II and III adenocarcinomas of the esophagogastric junction: long-term prognostic analysis of a prospective randomized controlled trial].
Tian Y; Wang Q; Wang J; Qiao XY; Zhang J; Lin YC; Li Y; Fan LQ; Yang PG; Zhao Q
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):128-137. PubMed ID: 33508918
[No Abstract] [Full Text] [Related]
7. The impact of preoperative radiochemotherapy on survival in advanced esophagogastric junction signet ring cell adenocarcinoma.
Bekkar S; Gronnier C; Messager M; Robb WB; Piessen G; Mariette C;
Ann Thorac Surg; 2014 Jan; 97(1):303-10. PubMed ID: 24200394
[TBL] [Abstract][Full Text] [Related]
8. Perioperative chemotherapy vs. neoadjuvant chemoradiation in gastroesophageal junction adenocarcinoma : A population-based evaluation of the Munich Cancer Registry.
Münch S; Habermehl D; Agha A; Belka C; Combs SE; Eckel R; Friess H; Gerbes A; Nüssler NC; Schepp W; Schmid RM; Schmitt W; Schubert-Fritschle G; Weber B; Werner J; Engel J
Strahlenther Onkol; 2018 Feb; 194(2):125-135. PubMed ID: 29071366
[TBL] [Abstract][Full Text] [Related]
9. A Prognostic Scoring Model for the Utility of Induction Chemotherapy Prior to Neoadjuvant Chemoradiotherapy in Esophageal Cancer.
Xi M; Liao Z; Deng W; Xu C; Komaki R; Blum M; Hofstetter WL; Ho L; Lin SH
J Thorac Oncol; 2017 Jun; 12(6):1001-1010. PubMed ID: 28351804
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant chemotherapy or chemoradiotherapy for adenocarcinoma of the esophagus.
Visser E; Edholm D; Smithers BM; Thomson IG; Burmeister BH; Walpole ET; Gotley DC; Joubert WL; Atkinson V; Mai T; Thomas JM; Barbour AP
J Surg Oncol; 2018 Jun; 117(8):1687-1696. PubMed ID: 29806960
[TBL] [Abstract][Full Text] [Related]
11. No Survival Difference with Neoadjuvant Chemoradiotherapy Compared with Chemotherapy in Resectable Esophageal and Gastroesophageal Junction Adenocarcinoma: Results from the National Cancer Data Base.
Al-Sukhni E; Gabriel E; Attwood K; Kukar M; Nurkin SJ; Hochwald SN
J Am Coll Surg; 2016 Dec; 223(6):784-792.e1. PubMed ID: 27641320
[TBL] [Abstract][Full Text] [Related]
12. Lymph node harvest in esophageal cancer after neoadjuvant chemoradiotherapy.
Shridhar R; Hoffe SE; Almhanna K; Weber JM; Chuong MD; Karl RC; Meredith K
Ann Surg Oncol; 2013 Sep; 20(9):3038-43. PubMed ID: 23625142
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant Therapy for Locally Advanced Esophageal Cancer Should Be Targeted to Tumor Histology.
Stiles BM; Kamel MK; Harrison SW; Rahouma M; Lee B; Nasar A; Port JL; Altorki NK
Ann Thorac Surg; 2019 Jan; 107(1):187-193. PubMed ID: 30278165
[TBL] [Abstract][Full Text] [Related]
14. Signet Ring Cell Histology Confers Worse Overall Survival in Treated Esophageal Adenocarcinoma.
Tang A; Rappaport J; Raja S; Bribriesco AC; Sudarshan M; Siddiqui HU; Raymond D; Murthy SC; Ahmad U
Ann Thorac Surg; 2021 Jan; 111(1):214-222. PubMed ID: 32579884
[TBL] [Abstract][Full Text] [Related]
15. Perioperative chemotherapy versus neoadjuvant chemoradiotherapy for esophageal or GEJ adenocarcinoma: A propensity score-matched analysis comparing toxicity, pathologic outcome, and survival.
Goense L; van der Sluis PC; van Rossum PSN; van der Horst S; Meijer GJ; Haj Mohammad N; van Vulpen M; Mook S; Ruurda JP; van Hillegersberg R
J Surg Oncol; 2017 Jun; 115(7):812-820. PubMed ID: 28267212
[TBL] [Abstract][Full Text] [Related]
16. Esophageal adenocarcinoma stage III: Survival based on pathological response to neoadjuvant treatment.
Schwameis K; Zehetner J; Hagen JA; Oh DS; Worrell SG; Rona K; Cheng N; Samaan J; Green KM; Lipham JC
Surg Oncol; 2017 Dec; 26(4):522-526. PubMed ID: 29113673
[TBL] [Abstract][Full Text] [Related]
17. Predictors of Disease Recurrence and Survival in Esophageal Adenocarcinomas With Complete Response to Neoadjuvant Therapy.
Agoston AT; Zheng Y; Bueno R; Lauwers GY; Odze RD; Srivastava A
Am J Surg Pathol; 2015 Aug; 39(8):1085-92. PubMed ID: 26076061
[TBL] [Abstract][Full Text] [Related]
18. Signet ring cells in esophageal and gastroesophageal junction carcinomas have a more aggressive biological behavior.
Nafteux PR; Lerut TE; Villeneuve PJ; Dhaenens JM; De Hertogh G; Moons J; Coosemans WJ; Van Veer HG; De Leyn PR
Ann Surg; 2014 Dec; 260(6):1023-9. PubMed ID: 24836142
[TBL] [Abstract][Full Text] [Related]
19. Quality of Life During and After Completion of Neoadjuvant Chemoradiotherapy for Esophageal and Junctional Cancer.
Noordman BJ; Verdam MGE; Onstenk B; Heisterkamp J; Jansen WJBM; Martijnse IS; Lagarde SM; Wijnhoven BPL; Acosta CMM; van der Gaast A; Sprangers MAG; van Lanschot JJB
Ann Surg Oncol; 2019 Dec; 26(13):4765-4772. PubMed ID: 31620943
[TBL] [Abstract][Full Text] [Related]
20. Signet Ring Cell Features are Associated with Poor Response to Neoadjuvant Treatment and Dismal Survival in Patients with High-Grade Esophageal Adenocarcinoma.
Solomon D; Abbas M; Feferman Y; Haddad R; Perl G; Kundel Y; Morgenstern S; Menasherov N; Kashtan H
Ann Surg Oncol; 2021 Sep; 28(9):4929-4940. PubMed ID: 33709175
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
